Guide to Targeted Therapies: Treatment Resistance in Lung Cancer PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Guide to Targeted Therapies: Treatment Resistance in Lung Cancer PDF full book. Access full book title Guide to Targeted Therapies: Treatment Resistance in Lung Cancer by Federico Cappuzzo. Download full books in PDF and EPUB format.
Author: Federico Cappuzzo
Publisher: Springer
ISBN: 3319207415
Category : Medical
Languages : en
Pages : 67
Get Book
Book Description
This text is a concise and up-to-date review, which discusses the background, development and mechanisms of resistance, testing methods and technology, current and emerging therapies and resources that clinicians can provide to their patients. Busy healthcare professionals who want a quick review of treatment resistance in lung cancer as well as a summary of current therapies will benefit from this succinct guide.
Author: Federico Cappuzzo
Publisher: Springer
ISBN: 3319207415
Category : Medical
Languages : en
Pages : 67
Get Book
Book Description
This text is a concise and up-to-date review, which discusses the background, development and mechanisms of resistance, testing methods and technology, current and emerging therapies and resources that clinicians can provide to their patients. Busy healthcare professionals who want a quick review of treatment resistance in lung cancer as well as a summary of current therapies will benefit from this succinct guide.
Author: Federico Cappuzzo
Publisher: Springer
ISBN: 3319030590
Category : Medical
Languages : en
Pages : 75
Get Book
Book Description
Guide to Targeted Therapies: EGFR Mutations in NSCLC is a speedy and up-to-date review, which discusses EGFR mutations, testing methods and technology, current and emerging therapies, and resources that clinicians can provide to their patients. Busy healthcare professionals who want a quick review of EGFR gene mutations as well as a summary of current therapies will benefit from this succinct guide.
Author: Marianne Davies
Publisher: Springer
ISBN: 9783030165529
Category : Medical
Languages : en
Pages : 0
Get Book
Book Description
This book aims to educate nurses and advanced practice providers (APP’s) about known mutations, availability of targeted therapy and the management of patients with non-small cell lung cancer (NSCLC). It will educate nurses and practitioners about the scope of therapy to assure safe and effective lung cancer treatment. In this era of personalized medicine, nurses and APP’s are responsible for guiding patients from diagnosis through treatment. This starts with the identification of patients that can benefit from these therapies, the key role of biopsy acquisition (ie. what to test, when and how often) and treatment selection based on the mutation identified. Readers will learn about the mechanisms of action, administration, potential adverse side effects and unique management strategies for these targeted agents. Lung cancer continues to be the leading cause of cancer death in the United States and worldwide. Recent advances in the identification of specific oncogenic mutations that drive cancer development, growth and metastasis have led to major paradigm shifts in lung cancer treatment. Sophisticated methods are required to identify specific mutations at the time of diagnosis. This book explains how molecularly targeted therapies have been developed that target these drivers. To date, several tyrosine kinase inhibitors have been approved to target the epidermal growth factor receptor (EGFR), EML4-ALK ,ROS1 and BRAF. Most recently, immune checkpoint inhibitors have been approved with some indication that efficacy may be enhanced for patients who overexpress PD-L1. While some driver mutations have been identified, there is ongoing investigation into additional mutations. In the case of driver mutations, lung cancers will develop resistance to therapy. This book provides nurses and APP’s with the mechanisms of resistance that have been identified such as T790 mutation and many others in the EGFR mutation, and shows how the next level of drug development is focused on identifying mechanisms of resistance and development of new agents that overcome these mutations. With this book in hand, nurses and practitioners will be able to navigate patients through this ever expanding field of lung cancer treatment.
Author: Justin F. Klamerus
Publisher: Jones & Bartlett Publishers
ISBN: 1449610757
Category : Medical
Languages : en
Pages : 197
Get Book
Book Description
Johns Hopkins Patients' Guide to Lung Cancer is a concise, easy-to-follow “how to” guide that puts you on the path to wellness by explaining lung cancer treatment from start to finish. It guides you through the overwhelming maze of treatment decisions, simplifies the complicated schedule that lies ahead, and performs the task of putting together your plan of care in layman's terms. Empower yourself with accurate, understandable information that will give you the ability to confidently participate in the decision making about your care and treatment.
Author: Karen L. Reckamp
Publisher: Springer
ISBN: 3319403893
Category : Medical
Languages : en
Pages : 322
Get Book
Book Description
This book describes the molecular mechanisms of lung cancer development and progression that determine therapeutic interventions in the era of genomics, when the rapid evolution in lung cancer diagnosis and treatment necessitates critical review of new results to integrate advances into practice. The text opens with background and emerging information regarding the molecular biology of lung cancer pathogenesis. Updated results regarding lung cancer prevention and screening are discussed, followed by chapters on diagnostic techniques and pathological evaluation. This leads on to a detailed presentation of treatment modalities, from surgery and radiation therapy to standard chemotherapy and targeted agents. The coverage includes resistance to therapy and the emergence of immunotherapy for lung cancer; in addition, the current evidence in respect of small cell lung cancer is summarized. The book presents insights from experts across disciplines to emphasize the importance of collaborative care. Advances in our understanding of issues in geriatric oncology and palliative care complete the comprehensive discussion of lung cancer.
Author: Ravi Salgia
Publisher: Springer
ISBN: 3030178323
Category : Medical
Languages : en
Pages : 238
Get Book
Book Description
This book contextualizes translational research and provides an up to date progress report on therapies that are currently being targeted in lung cancer. It is now well established that there is tremendous heterogeneity among cancer cells both at the inter- and intra-tumoral level. Further, a growing body of work highlights the importance of targeted therapies and personalized medicine in treating cancer patients. In contrast to conventional therapies that are typically administered to the average patient regardless of the patient’s genotype, targeted therapies are tailored to patients with specific traits. Nonetheless, such genetic changes can be disease-specific and/or target specific; thus, the book addresses these issues manifested in the somatically acquired genetic changes of the targeted gene. Each chapter is written by a leading medical oncologist who specializes in thoracic oncology and is devoted to a particular target in a specific indication. Contributors provide an in-depth review of the literature covering the mechanisms underlying signaling, potential cross talk between the target and downstream signaling, and potential emergence of drug resistance.
Author: Elaine Vickers
Publisher: John Wiley & Sons
ISBN: 1119126827
Category : Medical
Languages : en
Pages : 360
Get Book
Book Description
The accessible guide to the principles behind new, more targeted drug treatments for cancer Written for anyone who encounters cancer patients, cancer data or cancer terminology, but have no more than a passing knowledge of cell biology. A Beginner's Guide to Targeted Cancer Treatments provides an understanding of how cancer works and the many new treatments available. Using over 100 original illustrations, this accessible handbook covers the biology and mechanisms behind a huge range of targeted drug treatments, including many new immunotherapies. Dr Vickers translates a complex and often overwhelming topic into something digestible and easily understood. She also explains what cancer is, how it behaves and how our understanding of cancer has changed in recent years. Each chapter takes the reader through how new cancer drugs work and their benefits and limitations. With the help of this book, readers will be able to better understand more complex, in-depth articles in journals and books and develop their knowledge. This vital resource: Offers the latest insights into cancer biology Provides a broad understanding of how targeted cancer treatments work Describes many of the new immunotherapy approaches to cancer treatment, such as checkpoint inhibitors and CAR-modified T cells Helps readers feel confident discussing treatment options with colleagues and patients Provides an overview of which treatments are relevant to each of the most common solid tumours and haematological cancers, and the rationale behind them Demystifies the jargon – terms such as the EMT, cancer stem cells, monoclonal antibodies, kinase inhibitors, angiogenesis inhibitors etc. Explains the resistance mechanisms to many new treatments, including issues such as the way cancer cells diversify and evolve and the complex environment in which they live
Author: Rossella Bruno
Publisher: Frontiers Media SA
ISBN: 2832539394
Category : Medical
Languages : en
Pages : 116
Get Book
Book Description
Lung cancer is one of the leading causes of cancer-related death worldwide with a prevalence of advanced stage in up to 70% of cases and a five-year survival reached in only 5-10% of cases. Targeted therapies and immunotherapy have greatly improved the management of patients with advanced non-small cell lung cancer (NSCLC), particularly adenocarcinoma, and current diagnostic algorithms are based on the molecular analysis of several biomarkers necessary to tailor therapy. In detail, patients harboring sensitive driver alterations within the oncogenes EGFR, BRAF, ALK, ROS1, RET and NTRK1/2/3 can be treated with approved kinase inhibitors (KIs). In addition, drugs against MET, KRAS G12C and other markers are providing interesting results across different clinical trials. Targeted therapies have greatly improved therapeutic options for NSCLC, but resistance inevitably occurs usually after one year of treatment and some patients, although harboring sensitive alterations, never respond to treatment.
Author: Mary O'Brien
Publisher: Karger Medical and Scientific Publishers
ISBN: 3318070106
Category : Medical
Languages : en
Pages : 148
Get Book
Book Description
Despite an overall decrease in tobacco use, lung cancer (80–85% of which is non-small-cell lung cancer [NSCLC]) is still the leading cause of cancer death in both men and women worldwide. Annual low-dose CT screening of high-risk individuals has the potential to detect early-stage tumors, which can usually be successfully treated with a combination of surgery, radiotherapy and chemotherapy and, in some cases, targeted therapy. However, most patients with NSCLC still present with advanced or metastatic disease. For these patients, initial therapy is guided by the tumor’s molecular characteristics and patient’s performance status. Targeted therapies have significantly improved clinical outcomes and, for some patients with no targetable genetic alterations, immunotherapy has demonstrated significant overall survival benefit. This insightful guide is designed to bring you up to speed with the latest developments and is important reading for all health professionals and medical trainees working in this fast-moving field. Table of Contents: • Prevention and screening • Diagnosis and staging • Surgery • Radiotherapy • Systemic therapy in non-metastatic NSCLC • Systemic therapy in advanced-stage/metastatic disease without a molecular driver • Personalized treatment in advanced NSCLC • Oligometastatic disease and brain metastases
Author: David J. Stewart
Publisher: Springer Science & Business Media
ISBN: 160761524X
Category : Medical
Languages : en
Pages : 544
Get Book
Book Description
Defining the Lung Cancer Problem 1 Lung cancer is the leading cause of cancer death in the world. It kills almost as many Americans as cancers of the breast, prostate, colon, rectum, pancreas, and 2 kidney combined, and accounts for 28.6% of all US cancer deaths. With an increase in the 5-year relative survival rate from 13% to only 16% in the more than 2 30 years from 1974 to the present, it will take us another 840 years to eradicate lung cancer deaths if we do not improve the current rate of progress. As discussed in this text, lung cancer prevention has received substantial att- tion. The decrease in smoking in recent decades has helped, but smoking is not the only problem. Lung cancer in people who have never smoked is currently the 5th 3 leading cause of cancer death in the United States. Several factors contribute to the lethality of lung cancer, including the rapidity of tumor growth, advanced stage at diagnosis (due to nonspecificity of early sy- toms and the uncertain efficacy of screening), early development of metastases, and resistance to therapy. Several chapters in this book discuss new molecular targets that may be potentially exploitable in the future, as well as discussing our track record to date in exploiting them.
